332 related articles for article (PubMed ID: 30698272)
1. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.
Tepper SJ; Dodick DW; Schmidt PC; Kellerman DJ
Headache; 2019 Apr; 59(4):509-517. PubMed ID: 30698272
[TBL] [Abstract][Full Text] [Related]
2. Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial.
Dodick DW; Tepper SJ; Friedman DI; Gelfand AA; Kellerman DJ; Schmidt PC
Headache; 2018 Jul; 58(7):986-992. PubMed ID: 29782049
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine.
Spierings EL; Brandes JL; Kudrow DB; Weintraub J; Schmidt PC; Kellerman DJ; Tepper SJ
Cephalalgia; 2018 Feb; 38(2):215-224. PubMed ID: 29022755
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
Tuchman M; Hee A; Emeribe U; Silberstein S
CNS Drugs; 2006; 20(12):1019-26. PubMed ID: 17140280
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ).
Winner P; Farkas V; Štillová H; Woodruff B; Liss C; Lillieborg S; Raines S;
Headache; 2016 Jul; 56(7):1107-19. PubMed ID: 27329280
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
[TBL] [Abstract][Full Text] [Related]
7. Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy.
Lipton RB; Schmidt P; Diener HC
Headache; 2017 May; 57(5):756-765. PubMed ID: 28386945
[TBL] [Abstract][Full Text] [Related]
8. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
[TBL] [Abstract][Full Text] [Related]
9. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
Schulman EA
Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
[TBL] [Abstract][Full Text] [Related]
10. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
Gawel M; Aschoff J; May A; Charlesworth BR;
Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
[TBL] [Abstract][Full Text] [Related]
11. Intranasal zolmitriptan for the treatment of acute migraine.
Tepper SJ; Chen S; Reidenbach F; Rapoport AM
Headache; 2013 Sep; 53 Suppl 2():62-71. PubMed ID: 24024604
[TBL] [Abstract][Full Text] [Related]
12. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.
Dodick D; Brandes J; Elkind A; Mathew N; Rodichok L
CNS Drugs; 2005; 19(2):125-36. PubMed ID: 15697326
[TBL] [Abstract][Full Text] [Related]
13. Zolmitriptan for acute migraine attacks in adults.
Bird S; Derry S; Moore RA
Cochrane Database Syst Rev; 2014 May; 2014(5):CD008616. PubMed ID: 24848613
[TBL] [Abstract][Full Text] [Related]
14. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
15. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial.
Loder E; Freitag FG; Adelman J; Pearlmand S; Abu-Shakra S
Curr Med Res Opin; 2005 Mar; 21(3):381-9. PubMed ID: 15811207
[TBL] [Abstract][Full Text] [Related]
16. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine.
Gallagher RM; Dennish G; Spierings EL; Chitra R
Headache; 2000 Feb; 40(2):119-28. PubMed ID: 10759911
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Skin Tolerability of Intracutaneous Zolmitriptan Delivery in Swine Using Adhesive Dermally Applied Microarray.
Nguyen J; Lewis H; Queja A; Diep AN; Hochart G; Ameri M
J Pharm Sci; 2018 Aug; 107(8):2192-2197. PubMed ID: 29772224
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of zolmitriptan nasal spray in adolescent migraine.
Lewis DW; Winner P; Hershey AD; Wasiewski WW;
Pediatrics; 2007 Aug; 120(2):390-6. PubMed ID: 17671066
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel zolmitriptan intracutaneous microneedle system (Qtrypta™) for the acute treatment of migraine.
Rapoport AM; Ameri M; Lewis H; Kellerman DJ
Pain Manag; 2020 Nov; 10(6):359-366. PubMed ID: 32752932
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
Cady RK; McAllister PJ; Spierings EL; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
